Wczytywanie kursów wyceny...

Prognoza

Średnia cena docelowa analityków wynosi 111,27 € (+6,05%). Mediana wynosi 109,45 € (+4,32%).

Kupuj
  10
Trzymaj
  14
Sprzedaj
  2

Dyskusje w społeczności

Nie ma jeszcze dyskusji o tym aktywie.

Rozpocznij dyskusję

  • agilon health raises EBITDA forecast: turnaround driven by contract discipline and clinical programs

    At the Jefferies conference, agilon health said the shift from growth to profitability is showing initial success and raised its 2026 EBITDA forecast to $75–95 million. Improved contract terms, a new data pipeline, tighter cost control and advanced clinical programs—especially for heart failure—contributed to better risk-adjusted and cost outcomes. The company closed Q2 with $257 million in cash (excluding ACO units) and expects at least $125 million by year-end, but remains cautious due to medical cost sensitivity to small variances. » Więcej na de.investing.com


  • Agilon Health significantly beats Q2 expectations and raises full‑year outlook

    Agilon Health reported adjusted earnings of $1.04 per share in Q2 2026 (expectation $0.08) and revenue of $1.49 billion (expectation $1.44 billion), and subsequently raised its full‑year guidance for revenue, medical margin and adjusted EBITDA. The medical margin rose to $197 million and adjusted EBITDA to $70 million, despite a deliberate 12.3% reduction in Medicare Advantage membership. Management attributes the strong results to stricter contract discipline, improved risk adjustments and favorable cost trends. The stock jumped sharply and the company now expects about $5.8 billion in revenue and roughly $85 million of adjusted EBITDA for 2026. » Więcej na de.investing.com

Dane finansowe spółki

W ostatnim kwartale Agilon Health Inc osiągnęła przychody w wysokości 1,34 mld € i zysk netto w wysokości 30,82 mln €
(EUR) wrzesień 2026
YoY
Przychody 1,34 mld 9,68%
Zysk brutto 86,5 mln 250,07%
Zysk netto 30,82 mln 132,82%
EBITDA 41,84 mln 148,49%

Dane fundamentalne

Wskaźnik Wartość
Kapitalizacja rynkowa
1,76 mld €
Liczba akcji
16,8 mln
Maksimum/minimum z 52 tygodni
120,84 € - 6,79 €
Dywidendy Nie
Beta
3,11
C/Z (PE Ratio)
-17,66
PEG (PEG Ratio)
-0,30
C/WK (PB Ratio)
6,92
C/S (PS Ratio)
0,32

Profil spółki

Nazwa
Agilon Health Inc
CEO
Timothy O'Rourke
Pracownicy 856
🍪

Parqet  używa plików cookie. Dowiedz się więcej